Overview
Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called folate receptor alpha (FRα). It is being developed as maintenance therapy for the treatment of subjects with recurrent platinum-sensitive, highgrade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. Patients must have confirmation of FRα positivity by the Ventana FOLR1 Assay.
Principal investigator
Eligibility criteria
Exclusion Criteria: 1. Endometrioid, clear cell, mucinous, or sarconmatous histology; mixed tumors containing any of the above or low grade/borderline ovarian tumor 2. More than one line of prior chemotherapy before current/planned triplet therapy 3. PD (progressive disease) while on or following platinum-based therapy 4. Prior or whole-pelvis or wide-field radiotherapy 5. \> Grade 1 peripheral neuropathy 6. History of or concurrent ocular disorders 7. Grade 4 thromboembolic events 8. Not appropriate for bevacizumab treatment 9. Requiring use of folate-containing supplements 10. Prior hypersensitivity to monoclonal antibodies 11. Pregnant or breatfeeding women 12. Received prior MIRV or other FRα-targeting agents 13. Untreated or symptomatic central nervous system metastases 14. History of other malignancy within 3 years prior to signing study consent
Participate in this trial
Are you interested in enrolling in this study? Learn more here.
I'm Interested In ParticipatingFor Referring Providers
Do you have a patient you think would be a good candidate for this trial? Learn more about enrolling your patient.